SG Americas Securities
MRSN

SG Americas Securities’s Mersana Therapeutics MRSN Stock Holding History

SG Americas Securities’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,421
Closed -$12K – 3349
2025
Q1 		$12K Sell
1,421
-3,071
-68% -$47.4K ﹤0.01% 3408
2024
Q4 		$161K Buy
4,492
+1,003
+29% +$51.9K ﹤0.01% 2351
2024
Q3 		$165K Sell
3,489
-2,060
-37% -$90.9K ﹤0.01% 2641
2024
Q2 		$279K Buy
5,549
+4,208
+314% +$304K ﹤0.01% 2000
2024
Q1 		$150K Sell
1,341
-228
-15% -$22.7K ﹤0.01% 2206
2023
Q4 		$91K Sell
1,569
-297
-16% -$11.9K ﹤0.01% 2797
2023
Q3 		$59K Buy
+1,866
New +$88.7K ﹤0.01% 2902
2023
Q2 		– Sell
-1,864
Closed -$192K – 2841
2023
Q1 		$192K Sell
1,864
-93
-5% -$13.1K ﹤0.01% 2441
2022
Q4 		$287K Buy
1,957
+373
+24% +$63K ﹤0.01% 1956
2022
Q3 		$268K Sell
1,584
-318
-17% -$51.7K ﹤0.01% 2090
2022
Q2 		$220K Buy
+1,902
New +$179K ﹤0.01% 2603
2022
Q1 		– Sell
-651
Closed -$101K – 3275
2021
Q4 		$101K Sell
651
-818
-56% -$159K ﹤0.01% 3083
2021
Q3 		$346K Buy
+1,469
New +$429K ﹤0.01% 2813
2021
Q2 		– Sell
-500
Closed -$202K – 3091
2021
Q1 		$202K Buy
500
+229
+85% +$111K ﹤0.01% 2675
2020
Q4 		$180K Sell
271
-1,133
-81% -$630K ﹤0.01% 2688
2020
Q3 		$654K Buy
1,404
+726
+107% +$367K ﹤0.01% 1460
2020
Q2 		$397K Buy
678
+162
+31% +$55.3K ﹤0.01% 2292
2020
Q1 		$75K Buy
+516
New +$90.2K ﹤0.01% 3087

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SG Americas Securities's MRSN Position: Q2 2025 in Review

SG Americas Securities sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 1,421 shares — an estimated $12K sold.

SG Americas Securities first reported a position in MRSN in Q1 2020 and held it in 18 quarters. The position peaked at $654K in Q3 2020. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • SG Americas Securities reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 1,421 Mersana Therapeutics shares in Q2 2025, an estimated $12K.
  • SG Americas Securities first reported a position in Mersana Therapeutics in Q1 2020 and held it in 18 quarters.
  • SG Americas Securities's Mersana Therapeutics position peaked at $654K in Q3 2020.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.